Lilly and Boehringer's Jardiance, chasing AZ, nabs speedy FDA review in kidney disease

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Mar 12, 2020 at 11:13 PM.

  1. #1 cafead, Mar 12, 2020 at 11:13 PM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,990
    Likes Received:
    3
    via In its quest to keep pace with rising SGLT2 rival Farxiga from AstraZeneca, Eli Lilly and Boehringer Ingelheim's Jardiance has had its fair share of stumbles in recent months. But in kidney disease, where the class is racing to snatch share, it just nabbed a fast-track boost from the FDA.

    article source
     
    Quote

  2. #2 anonymous, Mar 12, 2020 at 11:15 PM
    anonymous

    anonymous Guest

     
    Quote
  3. #3 anonymous, Mar 12, 2020 at 11:17 PM
    anonymous

    anonymous Guest

    Guess what boys and girls, Invokana has the Indication, DKD and Rehospitalization for Heart Failure.
     
    Quote
  4. #4 anonymous, Mar 13, 2020 at 6:37 PM
    anonymous

    anonymous Guest

    Might want to be a little more specific on your indication regarding Heart Failure, seems like you guys/gals like to keep that very vague with your doctors. You lose a lot of credibility when we point it out in black and white.
    • Indicated to reduce the risk of end-stage kidney disease (ESKD), doubling of serum creatinine, cardiovascular (CV) death, and hospitalization for heart failure in adults with T2DM and diabetic nephropathy with albuminuria ˃300 mg/day
     
    Quote
Reply to Thread